GemVax's 'Liabex Injection' Validity Confirmed... "The Fruit of 30 Years of Research"
[Asia Economy Reporter Hyunseok Yoo] The pancreatic cancer treatment drug Liabaxju, developed by GemVax and Samsung Pharmaceutical, has confirmed its efficacy, raising expectations for commercialization.
According to industry sources on the 29th, the results of the Phase 3 clinical trial of Liabaxju (GV1001), developed by GemVax as a pancreatic cancer treatment, were announced the day before.
Samsung Pharmaceutical confirmed statistical significance (p=0.021) in the comparison of survival periods in the Phase 3 clinical trial, showing that the average survival period of the test group receiving Gemcitabine, Capecitabine, and additional Liabaxju was 339 days.
The currently most prescribed pancreatic cancer treatments are Folfirinox and Abraxane. Compared to the clinical results of Liabaxju, the company explained that Liabaxju shows the most outstanding effect among current pancreatic cancer treatments. Additionally, no specific side effects were identified, making it known as a drug that can be safely administered to pancreatic cancer patients.
Since 1989, GV1001, a telomerase-derived peptide, has been developed as an anticancer agent, starting large-scale clinical trials in Europe including the UK, and Samsung Pharmaceutical has produced successful results in the final Phase 3 clinical trial stage.
An industry official said, "The success rate of new drug development is around 0.02%, with an absolutely high failure rate, but even one successful new drug can lead to rapid growth into a global company," adding, "Considering that GemVax's research achievements have finally borne fruit, the potential of Liabaxju is highly significant."
Hot Picks Today
"Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- "Even If I Lose My Investment, the Government Will Cover It"... The Fund Attracting Retail Investors' Attention [Weekend Money]
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "I Went to 10 Convenience Stores and Still Couldn't Buy It": The Bread Sensation That Sold 100 Million Units Already [The Way We Shop Now]
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
Pancreatic cancer is considered one of the cancers with the lowest survival rates. The 5-year survival rate for pancreatic cancer is below 10%, and early diagnosis is difficult, with few alternative treatments available. Liabaxju is said to offer new hope to patients suffering from pancreatic cancer.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
